SACHIN MEHTA: Open Payments
NPI 1295926194 · BLUE BELL, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$306,740 in 379 payments from 16 companies in 2025. Trend: 2023 $114,581 · 2024 $178,492 · 2025 $306,740
Speaker / faculty: $214,642Honoraria: $42,763Travel & lodging: $27,152Consulting: $11,966Food & beverage: $10,217
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 82 | $92,633 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 95 | $73,566 |
| Axsome Therapeutics, Inc. | 49 | $47,859 |
| Teva Pharmaceuticals USA, Inc. | 38 | $37,400 |
| ABBVIE INC. | 46 | $28,729 |
| Alkermes, Inc. | 42 | $25,953 |
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Collegium Pharmaceutical, Inc. | 4 | $86 |
| Supernus Pharmaceuticals, Inc. | 4 | $80 |
Products named: COBENFY, CAPLYTA, Auvelity, UZEDY, VRAYLAR, LYBALVI, REXULTI, ARISTADA.
Industry payments across PA — which companies pay providers there.
